Leonteq Securities’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.4K Hold
200
– – ﹤0.01% 912
2026
Q2
$22.9K Buy
+200
New +$17.2K ﹤0.01% 939
2023
Q2
– Sell
-2,955
Closed -$87.6K – 1273
2023
Q1
$87.6K Hold
2,955
– – ﹤0.01% 667
2022
Q4
$73.8K Buy
+2,955
New +$78.8K ﹤0.01% 741
2022
Q2
– Sell
-2,477
Closed -$105K – 1315
2022
Q1
$105K Sell
2,477
-1,415
-36% -$59.8K ﹤0.01% 727
2021
Q4
$247K Buy
+3,892
New +$227K 0.01% 580

Other funds holding KYMR

Leonteq Securities's KYMR Position: Q3 2026 in Review

Leonteq Securities held its Kymera Therapeutics (KYMR) position steady in Q3 2026 at 200 shares worth $22.4K. The position accounts for ﹤0.01% of the portfolio, ranked #912.

Leonteq Securities first reported a position in KYMR in Q4 2021 and has held it in 6 quarters since. The position peaked at $247K in Q4 2021. 221 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Leonteq Securities held 200 shares of Kymera Therapeutics worth $22.4K as of Q3 2026.
  • Leonteq Securities left its Kymera Therapeutics share count unchanged in Q3 2026.
  • Kymera Therapeutics made up ﹤0.01% of Leonteq Securities's portfolio in Q3 2026, its #912 holding.
  • Leonteq Securities first reported a position in Kymera Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • Leonteq Securities's Kymera Therapeutics position peaked at $247K in Q4 2021.
  • 221 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.